Journal article · 2002 · Open access
Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?
Schizophrenia Bulletin, 28(2), 193–202 · Published 1 January 2002 · DOI 10.1093/oxfordjournals.schbul.a006931
In brief
“Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?” is a 2002 journal article by Jitschak G. Storosum and 5 co-authors, published in Schizophrenia Bulletin. OpenAlex counts 39 citations as of 20 November 2026. It is open access: the full text is free to read at Utrecht University Repository (Utrecht University).
- Citations
- 39
- Most cited in
- 2012 (5)
- Field-weighted impact
- 1.28
- References
- 52
- Authors
- 6
Abstract
In this article we report on a meta-analysis of the published studies of amisulpride conducted in order to demonstrate efficacy on primary negative symptoms in schizophrenia. Four placebo-controlled studies were conducted in patients with predominantly negative symptoms. In all studies a significant improvement was observed on the Scale for the Assessment of Negative Symptoms (SANS) in the amisulpride groups (50-300 mg daily) as compared to placebo. The improvement on the SANS was not accompanied by a simultaneous improvement on the Scale for the Assessment of Positive Symptoms (SAPS) or a decrease in extrapyramidal symptoms (EPS) in three of the four studies, indicating a genuine effect on primary negative symptoms. The overall analysis shows that the improvement on the SANS was accompanied by a small simultaneous improvement on the SAPS. Moreover, in the studies where depressive symptoms were measured, a significant improvement was also shown in favor of amisulpride. However, as the SAPS and the Montgomery Asberg Depression Rating Scale (MADRS) baseline scores were rather low, the improvement on both scales in favor of amisulpride is probably not responsible for the improvement on the SANS. A positive correlation was found between the severity on the mean SANS score at baseline and mean improvement at endpoint, and a surprisingly high success rate was observed in the placebo groups, indicating either that primary negative symptoms are not as persistent as had previously been thought, or that the concept of primary negative symptoms should be reconsidered. Probably amisulpride is efficacious on these nonenduring primary negative symptoms.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Storosum, J. G., Elferink, A., van Zwieten, B. J., VAN STRIK, R., Hoogendijk, W. J., & Broekmans, A. (2002). Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients? Schizophrenia Bulletin, 28(2), 193–202. https://doi.org/10.1093/oxfordjournals.schbul.a006931
MLA 9
Storosum, Jitschak G., et al. “Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?” Schizophrenia Bulletin, vol. 28, no. 2, 2002, pp. 193–202. https://doi.org/10.1093/oxfordjournals.schbul.a006931.
Chicago
Storosum, Jitschak G., A.J.A. Elferink, Barbara J. van Zwieten, ROEL VAN STRIK, Witte J.G. Hoogendijk, and A.W. Broekmans. 2002. “Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?” Schizophrenia Bulletin 28 (2): 193–202. https://doi.org/10.1093/oxfordjournals.schbul.a006931.
Harvard
Storosum, J. G. et al. (2002) ‘Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?’, Schizophrenia Bulletin, 28(2), pp. 193–202. doi:10.1093/oxfordjournals.schbul.a006931.
IEEE
J. G. Storosum, A. Elferink, B. J. van Zwieten, R. VAN STRIK, W. J. Hoogendijk, and A. Broekmans, “Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?,” Schizophrenia Bulletin, vol. 28, no. 2, pp. 193–202, 2002, doi: 10.1093/oxfordjournals.schbul.a006931.
BibTeX
@article{storosum2002amisulpride,
title = {{Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients?}},
author = {Storosum, Jitschak G. and Elferink, A.J.A. and van Zwieten, Barbara J. and VAN STRIK, ROEL and Hoogendijk, Witte J.G. and Broekmans, A.W.},
journal = {Schizophrenia Bulletin},
year = {2002},
volume = {28},
number = {2},
pages = {193--202},
doi = {10.1093/oxfordjournals.schbul.a006931},
url = {https://doi.org/10.1093/oxfordjournals.schbul.a006931}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2012 | 5 | |
| 2013 | 2 | |
| 2014 | 1 | |
| 2015 | 2 | |
| 2017 | 1 | |
| 2018 | 1 | |
| 2019 | 1 | |
| 2021 | 1 | |
| 2023 | 1 | |
| 2025 | 1 |
Its field-weighted citation impact is 1.28: it has been cited 1.28 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- amisulpride
- schizophrenia
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Storosum, J. G., Elferink, A., van Zwieten, B. J., VAN STRIK, R., Hoogendijk, W. J., & Broekmans, A. (2002). Amisulpride: Is There a Treatment for Negative Symptoms in Schizophrenia Patients? Schizophrenia Bulletin, 28(2), 193–202. https://doi.org/10.1093/oxfordjournals.schbul.a006931
How many times has this paper been cited?
39 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Utrecht University Repository (Utrecht University): sign in and open the full text from this page.
Who wrote this paper?
Jitschak G. Storosum, A.J.A. Elferink, Barbara J. van Zwieten, ROEL VAN STRIK, Witte J.G. Hoogendijk, A.W. Broekmans.
What is the DOI of this paper?
10.1093/oxfordjournals.schbul.a006931, permanently at https://doi.org/10.1093/oxfordjournals.schbul.a006931. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.